Login to Your Account



EnVivo Boldly Launches Solo Phase III in Schizophrenia

By Marie Powers
Staff Writer

Thursday, February 28, 2013
Eschewing the landscape of failures in central nervous system disorders, privately held EnVivo Pharmaceuticals Inc. showed moxie by initiating a Phase III program for lead compound EVP-6124, an alpha-7 agonist, in the lead indication of schizophrenia.

To continue reading subscribe now to Latest News

Learn More about Latest News

Already a subscriber? Sign In or Buy now to activate your subscription